WO2004032911A2 - Inhibition du facteur de croissance endothelial vasculaire - Google Patents

Inhibition du facteur de croissance endothelial vasculaire Download PDF

Info

Publication number
WO2004032911A2
WO2004032911A2 PCT/CA2003/001558 CA0301558W WO2004032911A2 WO 2004032911 A2 WO2004032911 A2 WO 2004032911A2 CA 0301558 W CA0301558 W CA 0301558W WO 2004032911 A2 WO2004032911 A2 WO 2004032911A2
Authority
WO
WIPO (PCT)
Prior art keywords
ealkyl
alkyl
ealkoxy
halo
compound
Prior art date
Application number
PCT/CA2003/001558
Other languages
English (en)
Other versions
WO2004032911A3 (fr
Inventor
Chaim M. Roifman
Amos J. Simon
Peter M. Demin
Olga B. Rounova
Original Assignee
The Hospital For Sick Children
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from CA002407755A external-priority patent/CA2407755A1/fr
Application filed by The Hospital For Sick Children filed Critical The Hospital For Sick Children
Priority to AU2003273702A priority Critical patent/AU2003273702A1/en
Priority to EP03757609A priority patent/EP1551381A2/fr
Priority to CA002500385A priority patent/CA2500385A1/fr
Priority to US10/530,800 priority patent/US20060241084A1/en
Publication of WO2004032911A2 publication Critical patent/WO2004032911A2/fr
Publication of WO2004032911A3 publication Critical patent/WO2004032911A3/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/275—Nitriles; Isonitriles
    • A61K31/277—Nitriles; Isonitriles having a ring, e.g. verapamil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Emergency Medicine (AREA)
  • Oncology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Hematology (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Transplantation (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La présente invention concerne des composés organiques thérapeutiques ainsi que l'inhibition de la sécrétion du facteur de croissance endothélial vasculaire (VEGF), et de ses effets, notamment de l'angiogenèse.
PCT/CA2003/001558 2002-10-11 2003-10-10 Inhibition du facteur de croissance endothelial vasculaire WO2004032911A2 (fr)

Priority Applications (4)

Application Number Priority Date Filing Date Title
AU2003273702A AU2003273702A1 (en) 2002-10-11 2003-10-10 Styrylacrylonitrile compounds for inhibition of vascular endothelial growth factor
EP03757609A EP1551381A2 (fr) 2002-10-11 2003-10-10 Inhibition du facteur de croissance endothelial vasculaire
CA002500385A CA2500385A1 (fr) 2002-10-11 2003-10-10 Inhibition du facteur de croissance endothelial vasculaire
US10/530,800 US20060241084A1 (en) 2002-10-11 2003-10-10 Inhibition of vascular endothelial growth factor

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US41764202P 2002-10-11 2002-10-11
US60/417,642 2002-10-11
CA002407755A CA2407755A1 (fr) 2002-10-11 2002-10-11 Inhibition de la secretion de facteur de croissance vegf
CA2,407,755 2002-10-11

Publications (2)

Publication Number Publication Date
WO2004032911A2 true WO2004032911A2 (fr) 2004-04-22
WO2004032911A3 WO2004032911A3 (fr) 2004-06-17

Family

ID=32094427

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CA2003/001558 WO2004032911A2 (fr) 2002-10-11 2003-10-10 Inhibition du facteur de croissance endothelial vasculaire

Country Status (3)

Country Link
EP (1) EP1551381A2 (fr)
AU (1) AU2003273702A1 (fr)
WO (1) WO2004032911A2 (fr)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1858542A2 (fr) * 2005-02-24 2007-11-28 Joslin Diabetes Center, Inc. Compositions et methodes permettant de traiter la permeabilite vasculaire
US20120309744A1 (en) * 2011-06-01 2012-12-06 NBI Pharmaceuticals, Inc. Dosing regimens and methods for treating or preventing hepatocellular carcinoma

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001079158A2 (fr) * 2000-04-13 2001-10-25 Hsc Research And Development Limited Partnership Nouveaux composes destines a la modulation de la proliferation cellulaire
WO2003030895A1 (fr) * 2001-10-11 2003-04-17 The Hospital For Sick Children Composes styryl acrylonitrile et utilisation desdits composes pour favoriser la myelopoiese
WO2003062190A1 (fr) * 2002-01-18 2003-07-31 The Hospital For Sick Children Composes destines a moduler la proliferation cellulaire

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001079158A2 (fr) * 2000-04-13 2001-10-25 Hsc Research And Development Limited Partnership Nouveaux composes destines a la modulation de la proliferation cellulaire
WO2003030895A1 (fr) * 2001-10-11 2003-04-17 The Hospital For Sick Children Composes styryl acrylonitrile et utilisation desdits composes pour favoriser la myelopoiese
WO2003062190A1 (fr) * 2002-01-18 2003-07-31 The Hospital For Sick Children Composes destines a moduler la proliferation cellulaire

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1858542A2 (fr) * 2005-02-24 2007-11-28 Joslin Diabetes Center, Inc. Compositions et methodes permettant de traiter la permeabilite vasculaire
EP1858542A4 (fr) * 2005-02-24 2009-08-19 Joslin Diabetes Center Inc Compositions et methodes permettant de traiter la permeabilite vasculaire
EP2500031A3 (fr) * 2005-02-24 2012-12-26 Joslin Diabetes Center, Inc. Compositions et procédés de traitement de la perméabilité vasculaire
US8841259B2 (en) 2005-02-24 2014-09-23 Joslin Diabetes Center Compositions and methods for treating vascular permeability
US20120309744A1 (en) * 2011-06-01 2012-12-06 NBI Pharmaceuticals, Inc. Dosing regimens and methods for treating or preventing hepatocellular carcinoma

Also Published As

Publication number Publication date
AU2003273702A1 (en) 2004-05-04
WO2004032911A3 (fr) 2004-06-17
AU2003273702A8 (en) 2004-05-04
EP1551381A2 (fr) 2005-07-13

Similar Documents

Publication Publication Date Title
TWI750218B (zh) sGC 刺激劑
US8642602B2 (en) Method of inhibiting fibrogenesis and treating fibrotic disease
EP2431036B1 (fr) Composés de lactone macrocyclique et procédés pour leur utilisation
US6432950B1 (en) Method for inhibiting neoplastic cells and related conditions by exposure to benzothienopyrimidine derivatives
JP2005537223A (ja) 酸化窒素供与体、組成物および使用法
JP6262225B2 (ja) オキサビシクロヘプタン類、および再灌流障害の治療のためのオキサビシクロヘプタン類
PL221491B1 (pl) Związki makrocykliczne, środek farmaceutyczny zawierający te związki oraz zastosowanie tych związków
CA2440037A1 (fr) Agents therapeutiques a base de derives benzimidazole
EA032094B1 (ru) Дейтерированный палбоциклиб
AU2003227454B2 (en) Medicament for therapeutic treatment of vascular disease
US20060241084A1 (en) Inhibition of vascular endothelial growth factor
JP6370801B2 (ja) 肝疾患または肝障害の治療のための使用および方法
JP2005501060A (ja) 硫黄含有有機硝酸化合物の使用法
WO2004032911A2 (fr) Inhibition du facteur de croissance endothelial vasculaire
US9676790B2 (en) Substituted thienotriazolodiazapines
TW200829261A (en) Method for controlling angiogenesis in animals
JP2000510824A (ja) エンドセリン拮抗薬を含有することを特徴とする心不全治療剤
WO2005099695A1 (fr) Systemes d'administration de medicament destine a la prevention et au traitement de maladies vasculaires
CA2500385A1 (fr) Inhibition du facteur de croissance endothelial vasculaire
RU2697551C2 (ru) Новые производные peg
JP2010526073A (ja) 癌または前癌性症状およびその他の症状の治療のためのジヒドロピリジン誘導体
CA2503962A1 (fr) Composes procedes et dispositifs inhibant les modifications neoproliferatives de la paroi des vaisseaux sanguins
CN108779083B (zh) 作为细胞色素p450抑制剂的四唑衍生物
KR100694004B1 (ko) 세포소멸을 유발시킬 수 있는 약제의 제조를 위한프로피오닐 ｌ-카르니틴의 용도
JP2005520806A (ja) がん治療を改善する併用療法におけるキナゾリノン化合物

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2500385

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2003757609

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2003757609

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2006241084

Country of ref document: US

Ref document number: 10530800

Country of ref document: US

NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Ref document number: JP

WWP Wipo information: published in national office

Ref document number: 10530800

Country of ref document: US